Is Your Cancer Treatment Plan Accurate? The Truth About Biological Effective Dose
"New research reveals potential inaccuracies in current radiotherapy calculations, urging caution and further investigation for better patient outcomes."
For over two decades, the biological effective dose (BED) has been a cornerstone in cancer treatment, offering a way to relate treatment outcome, to radiation dosage. While BED has become a useful metric, uncertainties have prevented its widespread adoption as a global standard. The BED, extrapolated from the linear-quadratic (LQ) model, helps compare the effectiveness of different fractionation schemes, ideally determining the best approach and prescribed dose for a given clinical outcome.
Traditionally, BED has been applied to single-phase treatment plans, where the treatment configuration and dose per fraction remain constant. However, modern treatment often involves multiple phases, such as a boost phase with different doses or varying fractions. Calculating BED in these multiphase scenarios introduces complexities, and current treatment planning systems (TPS) often struggle to accurately compute the true BED (BEDT).
A recent study has shed light on the accuracy of an approximate BED equation (BEDA) used in multiphase treatment plans. Researchers investigated the clinical precision and accuracy of BEDA relative to BEDT in patients with head and neck or prostate cancer, revealing important insights into the limitations of current calculation methods and the need for more precise approaches.
Why BED Accuracy Matters
Biological effective dose (BED) is intended to describe treatment effect rather than physical dose alone. One 2023 analysis found that BED values for acoustic neuroma radiosurgery had been overestimated when calculations used only beam-on time, because DNA repair continues during beam-off intervals. Other research focuses on complex double-strand breaks as lethal lesions and proposes normalizing targeted radionuclide therapy to biological effect rather than simply to the same physical dose.
From Ancient Treatment to Precision Care
Cancer has been documented since ancient Egyptian and Greek civilizations, although early treatment relied largely on radical surgery and cautery and was often ineffective. The National Cancer Institute's timeline presents landmark discoveries across 250 years of cancer research, while the Cancer History Project highlights advances supported by federal funding and clinical trials involving thousands of people with cancer. More recent reviews trace the evolution of targeted therapy and describe how earlier breakthroughs shaped modern precision cancer care.
Decoding Biological Effective Dose: Why Accuracy Matters
The study, recently published in 'Medical Dosimetry,' evaluated treatment plans from twenty patients—ten with head and neck cancer and ten with prostate cancer—using Pinnacle³ 9.2 treatment planning systems. Researchers focused on organs at risk (OARs) such as the normal brain, optic nerves, spinal cord, brainstem, bladder, and rectum. By comparing BEDA and BEDT distributions calculated using MATLAB 2010b, they assessed percent error, correlation coefficients, and agreement through Bland-Altman analysis.
- Inconsistency in Accuracy: The accuracy and consistency of BEDA calculations varied significantly depending on the specific organ being analyzed.
- Underestimation of True Dose: BEDA was found to consistently underestimate the true biological effective dose (BEDT), which could have implications for treatment planning.
- Error Range: Maximum errors in BEDA distributions ranged from 2% to 11%, with the bladder showing the highest error rates.
- Dependence on Treatment Phase: The study emphasized that the consistency and accuracy of BEDA strongly depend on the dose distributions of the different treatment phases.
Where BED Models Can Mislead
BED is widely used to compare fractionation regimens and estimate treatment expectations, but clinical oncologists are advised to interpret its modeling carefully. A 2020 evaluation tested three BED formulae with a multipopulation reaction-diffusion simulation to determine whether they produced equivalent effects under different treatment regimes. The linear-quadratic model remains widely used for estimating tissue effects across dose fractions, yet the comparison of formulas shows why a BED value should not automatically be treated as a direct clinical outcome.
Comparing Dose Approaches
Comparing BED values across radiotherapy platforms requires caution because treatment plans may use different proprietary dose-calculation algorithms. Those algorithmic differences can create dose discrepancies that also affect BED accuracy. For non-uniformly irradiated targets, researchers describe two approaches: averaging BED across target voxels or averaging the probability of tumor-cell survival.
The Path Forward: Enhancing Precision in Cancer Treatment
The study underscores the need for caution when using approximate BEDA calculations in multiphase cancer treatments. The variability in accuracy and the potential for underestimation highlight the importance of incorporating more precise BED calculation algorithms into current treatment planning systems. By accounting for the spatial distribution of dose and the unique characteristics of each treatment phase, clinicians can optimize treatment plans and improve patient outcomes. Further research is essential to refine BED calculations, reduce uncertainties, and explore new models that better capture the complexities of tissue response to radiation. Ultimately, enhancing precision in BED calculations will pave the way for more effective and personalized cancer treatments.
BED as One Modeling Tool
BED is widely used to compare the efficacy of different radiotherapy fractionation regimens and to evaluate normal-tissue responses. Tumor control probability (TCP) models provide another way to assess treatment response. Comparative work examining several fractionation regimens therefore places BED and TCP models side by side rather than treating BED as the only measure of therapeutic effect.
Moving Beyond Maximum Tolerated Dose
Classical phase 1 dose-finding designs were developed around a single toxicity endpoint and the maximum tolerated dose, particularly for cytotoxic drugs. With the emergence of molecular targeted agents and immunotherapies, the concept of optimal biological dose was introduced to consider efficacy as well as toxicity. The FDA finalized guidance in 2024 on optimizing dosage for prescription drugs and biological products used to treat oncologic diseases.
The Limits Beyond the Formula
Cancer research faces biological, technological, and systemic limitations that can slow the development of effective therapies and better patient outcomes. Traditional preclinical models may fail to reproduce cancer's complex biology accurately. Cancer care also continues to face drug resistance, treatment side effects, and unequal access to advanced treatments, reinforcing the need for interdisciplinary and patient-centered approaches.
Dose Decisions in Practice
Stereotactic body radiotherapy has been studied as a way to deliver a focused high BED for metastatic sarcomas, potentially addressing their relative radioresistance. In a 2025 real-world study of trastuzumab deruxtecan for metastatic breast cancer, reduced dose intensity had no significant effect on real-world progression-free survival or treatment-related toxicities. A separate retrospective study compared low-dose bevacizumab at 7.5 mg/kg every three weeks with high-dose bevacizumab at 15 mg/kg every three weeks in patients with FIGO stage III-IV high-grade serous ovarian cancer.